Top Markets
Coin of the day
Lytix Biopharma AS Lytix Biopharma AS

Lytix Biopharma AS

LYTIX
Rang in aandelen #24450
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Aandeelprijs
$0.78611575
Marktkapitalisatie
$60.45M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-12.06%
Land
NO
Handel Lytix Biopharma AS (LYTIX)

Categorie

Dividendrendementgeschiedenis voor Lytix Biopharma AS (LYTIX)
Het dividendrendement (TTM) van Lytix Biopharma AS (aandelsymbool: LYTIX) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Lytix Biopharma AS (LYTIX) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH